About 18 months after taking part in the inaugural Barclays Demo Day, it was great to return to Barclays’ Canary Wharf HQ to present Calla Lily Clinical Care again.

Last time, we were pitching our ambitious plans to transform drug delivery for women.

This time, those plans are bolder than ever– but now backed by meaningful evidence of our ability to execute:

💥 We’re now clinical-stage and dosing patients with Callavid®, we’ve announced our first strategic collaboration with Merck Healthcare, seen significant further interest given the versatility of our technology, grown support from world-leading pharma experts, and secured significant non-dilutive funding from the NIHR.

While Lara and I continue to navigate a rocket that’s gaining momentum and altitude, it’s exciting to pause for a brief moment and think about where we’ll be in another 18 months!

Thanks to the Barclays UK Demo Day and Barclays Eagle Labs teams for organising another great event and for including us as one of the 12 exciting companies on the Health track. 🚀🚀🚀